Basic Information
Bexsero
Regulatory Information
EMEA/H/C/002333
Authorised
January 13, 2013
November 15, 2012
35
August 26, 2024
Company Information
Italy
Via Fiorentina, 1 IT-53100 Siena
GLAXOSMITHKLINE VACCINES SRL
Active Substances Detail
outer membrane vesicles from neisseria meningitidis group b (strain nz 98/254)recombinant Neisseria meningitidis group B fHbp fusion proteinrecombinant Neisseria meningitidis group B NadA proteinrecombinant Neisseria meningitidis group B NHBA fusion protein
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Active immunisation against invasive disease caused by Neisseria meningitidis serogroup-B strains.
Overview Summary
Bexsero is a vaccine used to protect individuals from the age of two months against invasive meningococcal disease caused by one group of the bacterium Neisseria meningitidis (group B). Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spine) and septicaemia (blood infection). Bexsero contains parts of the bacteria N. meningitidis group B.